# Small Nuclear RNA: The Splicing Workhorse of the Cell


## Key Takeaways

- Small nuclear RNAs (snRNAs), primarily U1, U2, U4, U5, and U6, are non-coding RNA molecules essential for pre-mRNA splicing in eukaryotes. They form the catalytic and structural core of the spliceosome, a large ribonucleoprotein complex.
- U6 snRNA is the primary catalytic component, utilizing a two-metal-ion mechanism, evolutionarily conserved with group II self-splicing introns, to mediate the two transesterification reactions that excise introns and ligate exons.
- snRNAs are extensively modified post-transcriptionally (e.g., pseudouridylation, 2′-O-methylation) and assemble with Sm core proteins into small nuclear ribonucleoprotein particles (snRNPs), which are then recycled for multiple splicing rounds.
- Dysregulation or mutations in snRNA genes or their associated proteins can lead to severe human diseases, including retinitis pigmentosa and spinal muscular atrophy, highlighting their critical role in gene expression and cellular function.
- Therapeutic strategies are emerging, such as U1 snRNA-based therapies designed to correct specific splicing defects caused by mutations in splice sites, demonstrating the potential of targeting the splicing machinery for disease treatment.

---

## What Is Small Nuclear RNA?

Small nuclear RNA (snRNA) is a class of short, non-coding RNA molecules, typically 90 to 220 nucleotides in length, that reside predominantly within the nucleus of eukaryotic cells. The term "small" refers to their size relative to messenger RNA (mRNA), which can be thousands of nucleotides long. "Nuclear" indicates their primary subcellular location, though they are also found transiently in the cytoplasm during their own biogenesis. Unlike mRNA, snRNA does not encode protein. Instead, it functions as a structural and catalytic component of the spliceosome, the large ribonucleoprotein complex responsible for removing introns from precursor messenger RNA (pre-mRNA).

Each snRNA molecule is packaged with a set of proteins to form a small nuclear ribonucleoprotein particle (snRNP, pronounced "snurp"). The RNA component provides the specificity for recognizing [conserved sequences](/knowledge/molecular-biology/conserved-sequence) at intron-exon boundaries, while the associated proteins stabilize the complex and mediate conformational rearrangements. The snRNPs are among the most abundant RNA-protein complexes in the nucleus, with an estimated 10⁶ copies of the major splicing snRNPs per human cell.

The fundamental role of snRNA is to catalyze pre-mRNA splicing—the precise excision of non-coding introns and ligation of coding exons. This process is essential for generating mature, translatable mRNA from nearly all protein-coding genes in vertebrates, where the vast majority of genes contain introns. Without functional snRNA, splicing would not occur, and cells would be unable to produce functional proteins.

## The Discovery of snRNA

The history of snRNA begins in the 1960s, when investigators studying nuclear RNA metabolism in mammalian cells identified a population of small, stable RNA molecules that were distinct from ribosomal RNA (rRNA), transfer RNA (tRNA), and mRNA. These RNAs were initially detected by gel electrophoresis of nuclear extracts and were named according to their sedimentation properties or electrophoretic mobility. The "U" designation (for uridine-rich) was assigned because these RNAs were unusually rich in uridine residues.

In 1966, Harris Busch and colleagues at Baylor College of Medicine characterized a series of these small nuclear RNAs from rat liver nuclei, naming them U1 through U6 based on their abundance and electrophoretic migration. For nearly a decade, their function remained mysterious. The breakthrough came in the late 1970s, when the discovery of split genes and RNA splicing by Phillip Sharp and Richard Roberts (who shared the 1993 Nobel Prize in Physiology or Medicine) provided a context for these enigmatic molecules.

In 1979, Joan Steitz and Michael Lerner at Yale University made the critical connection. They found that antibodies from patients with the autoimmune disease systemic lupus erythematosus, which recognized the U1 snRNP, also precipitated pre-mRNA splicing intermediates. This suggested that U1 snRNA was physically associated with pre-mRNA during splicing. Subsequent work by Steitz's laboratory and others demonstrated that U1 snRNA base-pairs with the 5′ splice site of introns, and that the other U snRNAs (U2, U4, U5, U6) participate in the assembly of the active spliceosome. This work established snRNA as the central player in nuclear pre-mRNA splicing and opened the field of RNA-mediated catalysis in eukaryotes.

## Types of Small Nuclear RNA

The major spliceosomal snRNAs are designated U1, U2, U4, U5, and U6. These five RNAs are present in all eukaryotes and are required for the splicing of the vast majority of introns, which are known as U2-type introns. Each snRNA has a distinct role in the splicing reaction, and together they form the core of the spliceosome.

### U1, U2, and U4-U6 snRNAs

**U1 snRNA** is 164 nucleotides long in humans. Its 5′ end contains a sequence complementary to the conserved 9-[nucleotide sequence](/knowledge/molecular-biology/nucleotide-sequence) at the 5′ splice site of introns (the exon-intron junction). U1 snRNA initiates [spliceosome assembly](/knowledge/molecular-biology/spliceosome-assembly) by base-pairing with the 5′ splice site, committing the pre-mRNA to the splicing pathway.

**U2 snRNA** is 187 nucleotides long in humans. It recognizes the branch point sequence, a conserved adenosine residue located 18 to 40 nucleotides upstream of the 3′ splice site. U2 snRNA base-pairs with the branch point, bulging out the reactive adenosine that will attack the 5′ splice site during the first catalytic step of splicing. This interaction is stabilized by the protein SF3a and SF3b complexes, which are part of the U2 snRNP.

**U4 and U6 snRNAs** are 145 and 106 nucleotides long, respectively, in humans. They are unusual in that they are extensively base-paired to each other within a single U4/U6 di-snRNP particle. U6 is the catalytically essential RNA of the spliceosome; it participates directly in the chemistry of both transesterification reactions. U4 acts as a chaperone, holding U6 in an inactive conformation. During spliceosome activation, U4 is released, allowing U6 to rearrange and form the catalytic core with U2.

**U5 snRNA** is 116 nucleotides long in humans. It interacts with exon sequences at both the 5′ and 3′ splice sites, helping to align the two exons for ligation during the second catalytic step. U5 snRNA also contacts the loop of U6 snRNA, contributing to the architecture of the active site.

| snRNA | Length (human) | Key Binding Partner | Primary Function |
|-------|----------------|---------------------|------------------|
| U1 | 164 nt | 5′ splice site | Initiates [spliceosome assembly](/knowledge/molecular-biology/spliceosome-assembly) |
| U2 | 187 nt | Branch point sequence | Positions the reactive adenosine |
| U4 | 145 nt | U6 snRNA | Chaperone; inhibits premature U6 catalysis |
| U5 | 116 nt | Exon sequences at both splice sites | Aligns exons for ligation |
| U6 | 106 nt | U2 snRNA, pre-mRNA | Catalytic core of the spliceosome |

### Other snRNAs and variants

Beyond the major spliceosomal snRNAs, cells express a set of minor snRNAs—U11, U12, U4atac, U6atac, and U5—that function in the minor spliceosome. This distinct complex splices a rare class of introns (U12-type introns) that have different consensus sequences at their splice sites. U11 and U12 are functional analogs of U1 and U2, respectively, while U4atac and U6atac are analogs of U4 and U6. The minor spliceosome is present in all multicellular eukaryotes and is essential for development, even though U12-type introns constitute less than 0.5% of all human introns.

In addition, there are snRNAs that do not participate in splicing. For example, U7 snRNA is involved in the 3′ end processing of histone mRNAs, which are the only metazoan mRNAs that lack polyadenylated tails. U7 snRNA base-pairs with a conserved element downstream of the histone pre-mRNA cleavage site and recruits the cleavage machinery. Other snRNA-like molecules, such as the small Cajal body-specific RNAs (scaRNAs), guide modifications of other snRNAs and are discussed in the section on snRNA processing.

## How snRNA Works: The Splicing Mechanism

Pre-mRNA splicing occurs through two sequential transesterification reactions. In the first step, the 2′-hydroxyl of the branch point adenosine attacks the phosphate at the 5′ splice site, cleaving the pre-mRNA and forming a lariat intermediate. In the second step, the free 3′-hydroxyl of the upstream exon attacks the phosphate at the 3′ splice site, ligating the exons and releasing the intron lariat. The snRNAs orchestrate this chemistry by positioning the reactive groups and, in the case of U6, participating directly in catalysis.

### Spliceosome Assembly

Spliceosome assembly proceeds through a series of discrete complexes, designated E, A, B, and C, which can be distinguished biochemically by their sedimentation properties and protein composition. The assembly is highly ordered and requires ATP hydrolysis at several steps.

1. **Complex E (early complex):** U1 snRNP binds to the 5′ splice site through base-pairing between the 5′ end of U1 snRNA and the conserved intronic sequence. Simultaneously, the splicing factor U2AF (U2 auxiliary factor) binds to the polypyrimidine tract at the 3′ end of the intron, and the branch point binding protein SF1 (also called BBP in yeast) recognizes the branch point. This complex is ATP-independent and commits the pre-mRNA to the splicing pathway.

2. **Complex A (pre-spliceosome):** U2 snRNP joins the complex, displacing SF1. U2 snRNA base-pairs with the branch point sequence, bulging out the reactive adenosine. This interaction requires ATP and is stabilized by the U2 snRNP proteins SF3a and SF3b. The resulting complex is the first stable ATP-dependent splicing intermediate.

3. **Complex B (pre-catalytic spliceosome):** The U4/U6.U5 tri-snRNP joins the complex. This particle contains U5 snRNA, the U4/U6 base-paired duplex, and approximately 30 proteins. At this stage, U6 snRNA is still base-paired with U4 and is catalytically inactive.

4. **Complex B* (activated spliceosome):** The complex undergoes a major conformational rearrangement. U4 snRNA is released and degraded or recycled, and U6 snRNA refolds to base-pair with U2 snRNA, forming the catalytic core. This step requires the RNA helicase Prp28 (which disrupts the U1-5′ splice site interaction) and the Nineteen complex (NTC), a set of proteins that stabilize the activated conformation. The U6/U2 interaction creates a structure that resembles the catalytic center of group II self-splicing introns, strongly suggesting an evolutionary link.

5. **Complex C (catalytic spliceosome):** The first transesterification reaction occurs, cleaving the 5′ splice site and forming the lariat intermediate. The complex then rearranges for the second step, in which the exons are ligated. After splicing is complete, the mature mRNA is released, and the spliceosome disassembles, with the snRNPs recycled for additional rounds of splicing.

### Catalytic Role of snRNA

The question of whether splicing is RNA-catalyzed or protein-catalyzed was resolved in favor of RNA. The U6 snRNA is the key player. In the activated spliceosome, U6 snRNA forms an intramolecular stem-loop and base-pairs with U2 snRNA to create a structure in which a conserved region of U6, the ACAGAGA box, contacts the 5′ splice site. Mutations in this sequence abolish the first catalytic step, and crosslinking studies show that U6 is in direct contact with the reactive phosphate.

The catalytic mechanism is thought to involve a metal ion coordinated by U6 snRNA. In group II introns, which are self-splicing RNAs, two magnesium ions are coordinated by conserved RNA residues and catalyze the transesterification reactions. The spliceosome is believed to use the same two-metal-ion mechanism, with U6 snRNA providing the ligands for the metal ions. This was demonstrated experimentally by replacing specific oxygen atoms in U6 snRNA with sulfur atoms; the splicing reaction became dependent on manganese ions (which have a higher affinity for sulfur than magnesium does), providing strong evidence that the metal ions are coordinated by U6.

U2 snRNA also plays a direct catalytic role by positioning the branch point adenosine. The bulged adenosine is held in a specific orientation by base-pairing with U2, and its 2′-hydroxyl is positioned for nucleophilic attack on the 5′ splice site. U5 snRNA, meanwhile, aligns the two exons for the second step by base-pairing with the last few nucleotides of the upstream exon and the first few nucleotides of the downstream exon.

## snRNA Modifications and Processing

Like other stable RNAs, snRNAs undergo extensive post-transcriptional modification before they become functional. These modifications are guided by small nucleolar RNAs (snoRNAs) and occur in the nucleolus or Cajal bodies, subnuclear organelles named for their discoverer, the Spanish neuroanatomist Santiago Ramón y Cajal.

The most common modifications are pseudouridylation (the isomerization of uridine to pseudouridine) and 2′-O-methylation (the addition of a methyl group to the 2′-hydroxyl of the ribose sugar). Pseudouridine is formed by the enzyme dyskerin, which is guided to the correct position by a box H/ACA snoRNA that base-pairs with the target snRNA. 2′-O-methylation is catalyzed by fibrillarin, guided by a box C/D snoRNA. In human U2 snRNA, there are 13 pseudouridines and 10 2′-O-methylated residues; U6 snRNA has 7 pseudouridines and 12 2′-O-methylations. These modifications are clustered in regions of the snRNA that contact pre-mRNA or participate in catalysis, suggesting that they stabilize RNA-RNA interactions and fine-tune the splicing reaction.

The biogenesis of snRNA begins with transcription by RNA polymerase II (for all snRNAs except U6, which is transcribed by RNA polymerase III). The primary transcript receives a 7-methylguanosine cap at its 5′ end, which is then hypermethylated to a 2,2,7-trimethylguanosine cap in the cytoplasm. The snRNA is exported to the cytoplasm, where it assembles with the Sm core proteins—a ring of seven proteins (B/B′, D1, D2, D3, E, F, and G) that bind to a conserved sequence motif called the Sm site. The Sm core is essential for snRNA stability and for nuclear import. After re-import into the nucleus, the snRNA travels to Cajal bodies, where it undergoes final modification and assembly with snRNP-specific proteins.

The U6 snRNA is exceptional: it is transcribed by RNA polymerase III, has a γ-monomethyl phosphate cap instead of a trimethylguanosine cap, and does not associate with Sm proteins. Instead, it binds a related protein, LSm2-8, which recognizes a different sequence element at its 3′ end. U6 also undergoes a unique 3′ end processing event, in which a terminal uridine stretch is added post-transcriptionally.

## Methods Used to Study snRNA

Studying snRNA function requires methods that can capture both the RNA sequences and their dynamic interactions with pre-mRNA and proteins. Several complementary approaches are used.

**RNA sequencing (RNA-seq)** provides a global view of snRNA expression levels and can identify mutations or altered expression in disease. Standard RNA-seq libraries are often depleted of small RNAs, so snRNA analysis typically requires specialized protocols that enrich for RNAs in the 50-300 nucleotide range. Single-cell approaches, such as [Single Nuclear RNA-seq](/knowledge/molecular-biology/single-nuclear-rna-seq), can reveal cell-type-specific differences in snRNA expression, which is relevant because splicing patterns vary between cell types.

**Crosslinking and immunoprecipitation (CLIP)** is the gold standard for identifying RNA-RNA and RNA-protein interactions. In a typical CLIP experiment, cells are irradiated with ultraviolet light at 254 nm, which creates covalent crosslinks between RNA and proteins that are in direct contact. The snRNP of interest is immunoprecipitated using an antibody against a specific snRNP protein, and the crosslinked RNA is isolated and sequenced. Variants of this method, such as iCLIP (individual-nucleotide resolution CLIP) and eCLIP (enhanced CLIP), provide single-nucleotide resolution of binding sites. For RNA-RNA interactions, methods like SPLASH (split-pool ligation of transcriptomes) or MARIO (mapping RNA interactome in vivo) use psoralen crosslinking to capture base-pairing between snRNA and pre-mRNA.

**In vitro splicing assays** remain essential for dissecting the biochemical mechanism. HeLa cell nuclear extracts are incubated with a radiolabeled pre-mRNA substrate under splicing conditions (typically 20 mM HEPES pH 7.9, 60 mM KCl, 3.2 mM MgCl₂, 0.5 mM ATP, 20 mM creatine phosphate, and 2.6% polyvinyl alcohol, incubated at 30°C for 60-90 minutes). The products are separated by denaturing polyacrylamide gel electrophoresis and visualized by autoradiography. By depleting specific snRNPs from the extract (using [antisense oligonucleotides](/knowledge/molecular-biology/antisense-oligonucleotide) or affinity chromatography) and then adding back purified or in vitro-transcribed snRNA, investigators can test the function of specific snRNA sequences or modifications.

**Cryogenic electron microscopy (cryo-EM)** has revolutionized the field. In 2015-2016, several groups determined the structures of the yeast and human spliceosome at near-atomic resolution, revealing the precise arrangement of snRNAs and proteins in the catalytic core. These structures confirmed the central role of U6 snRNA in catalysis and showed how U2 and U6 form the RNA-based active site. The structures also revealed how the spliceosome undergoes large-scale conformational rearrangements during assembly and catalysis.

**[Fluorescence microscopy](/knowledge/diagnostics/imaging/fluorescence-microscopy-principles-applications-and-image-acquisition)** allows visualization of snRNP dynamics in living cells. By tagging snRNP proteins with fluorescent proteins (e.g., GFP) or using fluorescently labeled antisense oligonucleotides that bind snRNA, investigators can track the movement of snRNPs between nuclear speckles (storage sites), Cajal bodies (assembly sites), and sites of active transcription. Fluorescence recovery after photobleaching (FRAP) experiments have shown that snRNPs are highly mobile and are continuously recycled through the splicing cycle.

## snRNA in Disease and Medicine

Given the essential role of snRNA in gene expression, it is not surprising that mutations or dysregulation of snRNA genes cause disease. Because snRNA genes are present in multiple copies in the genome (for example, there are approximately 30 copies of the U1 snRNA gene in humans), a single mutation in one copy may have a mild effect, but mutations affecting the majority of copies can be pathogenic.

**Retinitis pigmentosa (RP)** is a degenerative eye disease caused by mutations in several splicing factors, including PRPF31, a protein component of the U4/U6.U5 tri-snRNP. Patients with RP have progressive loss of rod photoreceptors, leading to night blindness and eventual loss of vision. The disease mechanism is thought to involve haploinsufficiency—having only one functional copy of the gene—which reduces the efficiency of tri-snRNP assembly and makes photoreceptor cells, which have exceptionally high metabolic demands, particularly vulnerable.

**Spinal muscular atrophy (SMA)** is caused by mutations in the SMN1 gene, which encodes the survival of motor neuron protein. SMN is required for the assembly of the Sm core onto snRNAs. Without functional SMN, snRNP biogenesis is impaired, leading to reduced levels of functional snRNPs and widespread splicing defects. Motor neurons are selectively vulnerable, likely because they require particularly efficient splicing. The approved therapy nusinersen (Spinraza) is an [Antisense Oligonucleotide](/knowledge/molecular-biology/antisense-oligonucleotide) that promotes inclusion of exon 7 in SMN2, a nearly identical copy of SMN1 that normally produces a truncated, unstable protein. By increasing the amount of full-length SMN protein, nusinersen restores snRNP assembly and ameliorates the disease.

**Cancer** is associated with altered snRNA expression. For example, U1 snRNA is overexpressed in many cancers, and this overexpression is associated with increased usage of alternative cleavage and polyadenylation sites, leading to shortened 3′ untranslated regions and increased oncogene expression. Conversely, mutations in U1 snRNA have been found in a subset of cancers, where they can create cryptic splice sites and disrupt normal splicing patterns. The U1 snRNA gene is also a frequent integration site for the hepatitis B virus in hepatocellular carcinoma, suggesting that viral integration can disrupt snRNA function.

**Therapeutic applications** are emerging. Because snRNAs are essential for splicing, they are attractive targets for modulating gene expression. Modified U1 snRNAs have been designed to correct splicing defects caused by mutations in the 5′ splice site; these "U1 snRNA-based therapies" use a U1 snRNA with a modified 5′ end that base-pairs with a mutant splice site and restores correct splicing. This approach has shown promise in cell and animal models of diseases such as β-thalassemia and Duchenne muscular dystrophy. Additionally, the [Small RNA Containing Particles](/knowledge/molecular-biology/small-rna-containing-particles) field has explored using snRNP components to deliver therapeutic RNAs to the nucleus.

## Common Misconceptions and Pitfalls

Several misunderstandings are common among students first encountering snRNA.

**Confusing snRNA with siRNA or miRNA.** [Small interfering RNA](/knowledge/molecular-biology/small-interfering-rna) (siRNA) and microRNA (miRNA) are also small non-coding RNAs, but they function in the cytoplasm to silence gene expression post-transcriptionally. siRNAs are typically 21-23 nucleotides long and are generated from double-stranded RNA precursors, while miRNAs are ~22 nucleotides long and are processed from hairpin precursors. In contrast, snRNAs are 90-220 nucleotides long, are nuclear, and function in splicing. The distinction is fundamental: snRNA is part of the RNA processing machinery, while siRNA and miRNA are regulators of mRNA stability and translation. See [Small RNA vs Microrna](/knowledge/molecular-biology/small-rna-vs-microrna) and [Small Interfering RNA](/knowledge/molecular-biology/small-interfering-rna) for further clarification.

**Thinking snRNA is a template for protein synthesis.** snRNA is non-coding. It does not contain codons and is never translated into protein. Its function is structural and catalytic within the spliceosome. This is a common pitfall because students often assume that all RNA is mRNA-like.

**Believing that snRNA is the same as mRNA.** Messenger RNA carries the genetic information from DNA to the ribosome and is translated into protein. snRNA is a permanent component of the splicing machinery and is reused for many rounds of splicing. The two molecules are entirely different in function, structure, and fate.

**Assuming that all splicing is performed by proteins.** The discovery that U6 snRNA is the catalytic component of the spliceosome was surprising because it demonstrated that RNA, not protein, catalyzes the chemistry of splicing. This is consistent with the "RNA world" hypothesis, which posits that RNA preceded proteins as the primary catalyst in early life. Students should understand that the spliceosome is a ribozyme—an RNA enzyme—with proteins playing supporting roles.

**Overlooking the distinction between snRNA and snoRNA.** Small nucleolar RNA (snoRNA) is a related but distinct class of RNA that guides chemical modifications of rRNA, tRNA, and snRNA. The names are similar, but the functions and locations differ: snoRNAs are found in the nucleolus and Cajal bodies, while snRNAs are found throughout the nucleus and function in splicing.

**Assuming that snRNA mutations are always lethal.** Because snRNA genes are present in multiple copies, a mutation in a single copy may have little or no phenotypic effect. Pathogenic mutations typically affect the majority of copies or disrupt a rate-limiting step in snRNP biogenesis. This redundancy is an important evolutionary feature that buffers against mutations.

## Summary and Key Takeaways

Small nuclear RNA is a class of short, non-coding RNAs that function as the catalytic and structural core of the spliceosome. The five major snRNAs—U1, U2, U4, U5, and U6—work together to recognize splice sites, position the reactive groups, and catalyze the two transesterification reactions that remove introns from pre-mRNA. U6 snRNA is the catalytic heart of the spliceosome, using a two-metal-ion mechanism that is evolutionarily related to group II self-splicing introns. snRNAs are extensively modified post-transcriptionally, are assembled into snRNPs with Sm core proteins, and are recycled through many rounds of splicing. Mutations or dysregulation of snRNA genes cause diseases such as retinitis pigmentosa and spinal muscular atrophy, and snRNA-based therapies are being developed to correct splicing defects. Understanding snRNA is essential for appreciating the complexity of gene expression and the central role of RNA catalysis in eukaryotic biology.

## Frequently Asked Questions

### What is small nuclear RNA?

Small nuclear RNA (snRNA) is a class of short, non-coding RNA molecules, typically 90 to 220 nucleotides long, found predominantly in the nucleus of eukaryotic cells. It does not encode protein but instead functions as a structural and catalytic component of the spliceosome, the complex that removes introns from pre-mRNA during splicing.

### What is the function of small nuclear RNA?

The primary function of snRNA is to catalyze pre-mRNA splicing. The major snRNAs (U1, U2, U4, U5, U6) recognize conserved sequences at intron-exon boundaries, position the reactive groups for the two transesterification reactions, and provide the catalytic core of the spliceosome. U6 snRNA is the catalytic RNA that directly participates in the chemistry of splicing.

### What are the types of small nuclear RNA?

The major spliceosomal snRNAs are U1, U2, U4, U5, and U6. U1 recognizes the 5′ splice site, U2 recognizes the branch point, U4 acts as a chaperone for U6, U5 aligns the exons, and U6 provides the catalytic core. A minor set of snRNAs (U11, U12, U4atac, U6atac) functions in the minor spliceosome, which splices a rare class of introns. U7 snRNA is involved in histone mRNA processing.

### Where is small nuclear RNA found?

snRNA is found primarily in the nucleus, where it is concentrated in nuclear speckles (storage sites), Cajal bodies (assembly and modification sites), and at sites of active transcription where splicing occurs. During biogenesis, snRNA transiently travels to the cytoplasm to acquire the Sm core proteins before being re-imported into the nucleus.

### How does small nuclear RNA work?

snRNA works by base-pairing with conserved sequences in pre-mRNA and with other snRNAs. U1 and U2 snRNAs recognize the 5′ splice site and branch point, respectively. U6 snRNA then rearranges to form the catalytic core with U2, coordinating metal ions that catalyze the two transesterification reactions. U5 snRNA aligns the exons for ligation. The entire process requires ATP and involves multiple conformational rearrangements.

### Is small nuclear RNA the same as messenger RNA?

No. Messenger RNA (mRNA) carries the genetic code from DNA to the ribosome and is translated into protein. snRNA is non-coding and functions as a catalytic and structural component of the spliceosome. snRNA is stable and reused for many rounds of splicing, whereas mRNA is typically degraded after translation.

### What is the difference between snRNA and siRNA?

[Small interfering RNA](/knowledge/molecular-biology/small-interfering-rna) (siRNA) is a class of double-stranded RNA molecules, typically 21-23 nucleotides long, that function in the cytoplasm to silence gene expression by guiding the cleavage of complementary mRNAs. snRNA is longer (90-220 nucleotides), is single-stranded, is nuclear, and functions in splicing. siRNAs are generated from exogenous or endogenous double-stranded RNA precursors, while snRNAs are transcribed from dedicated genes and processed through a distinct biogenesis pathway.

## Further Reading

- Antonarakis SE. *Small nuclear RNA genes in Mendelian disorders*. Nature genetics. 2026. [PubMed 41345251](https://doi.org/10.1038/s41588-025-02440-7)
- Greene D et al. *Mutations in the small nuclear RNA gene RNU2-2 cause a severe neurodevelopmental disorder with prominent epilepsy*. Nature genetics. 2025. [PubMed 40210679](https://doi.org/10.1038/s41588-025-02159-5)
- Mehta PR et al. *U7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral Sclerosis*. bioRxiv : the preprint server for biology. 2025. [PubMed 41394711](https://doi.org/10.1101/2025.11.26.690143)
- Wang Y et al. *N(6)-methyladenosine in 7SK small nuclear RNA underlies RNA polymerase II transcription regulation*. Molecular cell. 2023. [PubMed 37820733](https://doi.org/10.1016/j.molcel.2023.09.020)
- Byrne SM et al. *An engineered U7 small nuclear RNA scaffold greatly increases ADAR-mediated programmable RNA base editing*. Nature communications. 2025. [PubMed 40419487](https://doi.org/10.1038/s41467-025-60155-z)
- Egloff S, Studniarek C, Kiss T. *7SK small nuclear RNA, a multifunctional transcriptional regulatory RNA with gene-specific features*. Transcription. 2018. [PubMed 28820318](https://doi.org/10.1080/21541264.2017.1344346)

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)